| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00818961 Details | 2013-12-18 Interventional | 2 | 36 | Alemtuzumab Busulfan Cyclophosphamid… Fludarabine Fludarabine pho… Methotrexate Rituximab Tacrolimus Leukemia Lymphoma Myelodysplastic… Myelodysplastic… Myeloproliferat… Preleukemia Myelodysplastic… | terminated early due to meeting end point with fewer patients than anticipated - | |||
| NCT00402415 Details | 2013-12-18 Interventional | 1 | 18 | Sirolimus Sunitinib Neoplasms Tumors | - - | |||
| NCT00324831 Details | 2013-12-18 Interventional | 3 | - | Antibodies Antibodies, Mon… Cyclophosphamid… Doxorubicin Immunoglobulin … Immunoglobulins Immunomodulatin… Liposomal doxor… Prednisone Rituximab Sargramostim Vaccines Vincristine Lymphoma Lymphoma, Large… | - - | |||
| NCT01220258 Details | 2013-12-16 Interventional | 2 | 29 | Azithromycin Ophthalmic Solu… Conjunctivitis Posterior Bleph… | - - | |||
| NCT01090973 Details | 2013-12-16 Interventional | 2 | 1 | Histone Deacety… Panobinostat Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, Mantl… Non-Hodgkin's L… | Pharmaceutical company request. The study was abandoned after only one patient due to low accrual and the sponsor losing interest in the single-agent. The one patient had disease progression requiring more aggressive treatment and did not complete the study. | |||
| NCT00070239 Details | 2013-12-16 Interventional | 1 | 100 | Alvocidib Fluorodeoxygluc… Hematologic Neo… Hematopoietic/L… Unspecified Adu… | - - | |||
| NCT01092546 Details | 2013-12-13 Interventional | 3 | 12 | Flutemetamol Hydrocephalus Hydrocephalus, … Normal Pressure… | Changed focus of the program - | |||
| NCT00033423 Details | 2013-12-13 Interventional | 1 | [1 Refs] | 18 | Rituximab Lymphoma Lymphoma, Non-H… | - - | ||
| NCT00000600 Details | 2013-12-13 Interventional | 2 | - | Vitamin E Vitamins Arteriosclerosi… Atherosclerosis Cardiovascular … Carotid Artery … Cerebrovascular… Heart Diseases Intracranial Ar… Vascular Diseas… | - - | |||
| NCT02010411 Details | 2013-12-12 Interventional | 2 | 17 | Alpha 1-Antitry… Cystic Fibrosis Fibrosis | Technical problems with measure of CFU's. Outcomes published: PMID:16986483 - | |||
| NCT01728480 Details | 2013-12-11 Interventional | 1 | 0 | Cisplatin Carcinoma Carcinoma, Squa… Carcinoma, Verr… Laryngeal Disea… Laryngeal Neopl… Mucositis Nasopharyngeal … Oropharyngeal N… Paranasal Sinus… Recurrence Squamous Cell C… Tongue Neoplasm… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Verru… Recurrent Verru… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Verru… Stage III Verru… Stage IV Squamo… Stage IV Squamo… Stage IVA Squam… Stage IVA Squam… Stage IVA Squam… Stage IVA Squam… Stage IVA Verru… Stage IVA Verru… Stage IVB Squam… Stage IVB Squam… Stage IVB Squam… Stage IVB Squam… Stage IVB Verru… Stage IVB Verru… Stage IVC Squam… Stage IVC Squam… Stage IVC Squam… Stage IVC Squam… Stage IVC Verru… Stage IVC Verru… Tongue Cancer | Financial Sponsor requested termination - | |||
| NCT00528671 Details | 2013-12-11 Interventional | 4 | 1571 | Phenprocoumon Hemorrhage Mechanical Hear… | - - | |||
| NCT00071942 NCT00077571 Details | 2013-12-11 Interventional | 1 | - | Metronidazole Vaccines Breast Neoplasm… Breast Neoplasm… Male Breast Can… Recurrent Breas… Stage IV Breast… | - - | |||
| NCT01370876 Details | 2013-12-10 Interventional | 2 | - | Oxaliplatin Head and Neck N… Cancer of the H… Neoplasms, Head… | company policy - | |||
| NCT00801736 2007-007639-17 Details | 2013-12-10 Interventional | 3 | 648 | Cisplatin Paclitaxel Lung Neoplasms Lung Cancer | The antibody used did not appear prognostic/predictive based on interim results. - | |||
| NCT00278122 Details | 2013-12-10 Interventional | 2 | - | Paclitaxel Sargramostim Melanoma Melanoma (Skin) | - - | |||
| NCT00107471 Details | 2013-12-10 Interventional | 1/2 | 7 | Lenograstim Topotecan Central Nervous… Glioma Nervous System … Brain Tumors Central Nervous… | The unpromising experience of the French group with topotecan given at a dosage of 0.4
mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792). - | |||
| NCT01373970 Details | 2013-12-06 Interventional | 4 | 184 | Pantoprazole Dyspepsia Functional Dysp… | - - | |||
| NCT01900795 Details | 2013-12-05 Interventional | 2 | 114 | Ibuprofen Pain, Postopera… Postsurgical Pa… | Terminated early due to administrative reasons not related to safety. - | |||
| NCT00857649 Details | 2013-12-05 Interventional | 3 | [1 Refs] | 369 | Memantine Alzheimer Disea… Alzheimer's Dis… | - Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site) |